Saturday, 10 October 2026European Markets

NR21 Stock Jump On Tuesday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with nr21 (nr21.pa) rising 9.58% to €91.50 on tuesday, after five successive sessions in a row of losses. cac 40 rose 0.43% to €7,215.58, following the last session's upward trend on what was a somewhat bullish trend trading session today.

nr21's last close was €83.50, 63.38% under its 52-week high of €228.00.

about nr21

nr21 société anonyme does not have significant operations. previously, it was involved in design and distribution of underwear and indoor clothing for men, women, and children. the company is based in paris, france.

earnings per share

as for profitability, nr21 has a trailing twelve months eps of €-1.17.

volatility

nr21's last week, last month's, and last quarter's current intraday variation average was a negative 6.59%, a negative 5.92%, and a positive 6.43%.

nr21's highest amplitude of average volatility was 6.59% (last week), 5.92% (last month), and 6.43% (last quarter).

moving average

nr21's worth is under its 50-day moving average of €94.28 and way under its 200-day moving average of €114.65.

more news about nr21 (nr21.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com